Peptides for Depression & Mood Support

Peptides may influence mood and depressive symptoms through several neurobiological mechanisms:

1. GABAergic and Serotonergic Modulation Selank, a synthetic analogue of the endogenous immunomodulatory peptide tuftsin, has been shown to influence GABAergic and serotonergic neurotransmission in animal models and limited human studies. It enhances GABA-A receptor sensitivity and modulates serotonin metabolism, producing anxiolytic and mood-stabilising effects. In Russian clinical practice (where it is an approved medication), Selank is used for anxiety and neurasthenic conditions. Its dual action on GABA and serotonin systems is relevant to the comorbidity of anxiety and depression — conditions that co-occur in approximately 60% of affected individuals.

2. BDNF and Neurotrophic Factor Enhancement Brain-derived neurotrophic factor (BDNF) is a critical mediator of neuronal survival, synaptic plasticity, and neurogenesis — processes increasingly recognised as impaired in depression. Reduced BDNF levels are consistently found in depressed individuals, and successful antidepressant treatment is associated with BDNF normalisation. Semax, a synthetic ACTH(4-10) analogue, has demonstrated significant BDNF upregulation in animal studies and limited human research, promoting neuroplasticity and cognitive function. This neurotrophic mechanism represents a distinct approach from traditional monoamine-based antidepressants.

3. Dopaminergic and Serotonergic Pathway Effects BPC-157 has demonstrated complex interactions with multiple neurotransmitter systems in preclinical studies. It has shown effects on the dopaminergic system — modulating dopamine turnover, receptor sensitivity, and dopamine-related behaviours. It also influences serotonergic pathways and has demonstrated protective effects against dopamine system damage in animal models. Anhedonia (loss of pleasure) — a core depressive symptom — is closely linked to dopaminergic dysfunction, making BPC-157's dopaminergic effects of particular theoretical interest.

4. Sleep Architecture Normalisation Sleep disruption is both a symptom and a contributing factor in depression — approximately 80% of depressed individuals experience insomnia or hypersomnia, and sleep disturbance often precedes depressive episodes. DSIP (delta-sleep-inducing peptide) specifically promotes delta-wave (slow-wave) sleep — the most restorative sleep phase. Normalising sleep architecture may address a key maintaining factor in depression, as impaired slow-wave sleep disrupts emotional processing, memory consolidation, and hormonal regulation (including cortisol and growth hormone).

5. Neuroinflammation Reduction The neuroinflammatory hypothesis of depression proposes that chronic low-grade inflammation — particularly elevated pro-inflammatory cytokines (IL-6, TNF-alpha, CRP) — contributes to depressive symptomatology through effects on neurotransmitter metabolism, HPA axis dysregulation, and neuroplasticity impairment. Several peptides possess anti-inflammatory properties that may address this pathway. BPC-157 modulates inflammatory cytokines. Selank has immunomodulatory effects (as a tuftsin analogue). Oxytocin has been shown to reduce neuroinflammatory markers and stress-related cortisol release.